On April 11th, the British newspaper The Daily Telegraph published a feature article about HAMLET and the founder of Hamlet Pharma Professor Catharina Svanborg, following a key-note lecture at the 12th International Breastfeeding and Lactation Symposium in Florence, Italy on April 8.
The lecture covered the HAMLET discovery, research into the molecular characteristics of the complex as well as the mechanisms of tumor cell death and the effects of HAMLET in patients and tumor models.
The HAMLET project was also featured on Italian television, Channel Rai 3, in the program on science and society entitled Leonardo. Following the symposium, papers on HAMLET and other key presentations were published in the Italian journal Annali dell’Istituto Superiore di Sanità.
More information and links to the interview and discussions from the conference as well as the article in The Daily Telegraph can be found on Hamlet Pharma’s home page.
For more information, please contact
Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46-709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About Hamlet Pharma
Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. Alpha1H is a peptide that includes key tumoricidal motifs within HAMLET. Together with oleic acid, Alpha1H forms a complex that target cancer tissues selectively similar to HAMLET. Alpha1H will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha- lactalbumin Made LEthal to Tumor cells.